Jan 24,2019

Real-World Data based on Kaiku Health Immune Checkpoint Inhibitor Module published in Journal of Cancer Research and Clinical Oncology

Kaiku Health, Oulu University Hospital and Docrates Cancer Center have published first data on the symptoms reported by cancer patients receiving immune checkpoint inhibitor (ICI) therapies in a real-world setting. The purpose of the study was to investigate whether symptoms reported by cancer patients using the Kaiku Health ICI module corresponded to symptoms reported in earlier clinical trials. The study also sought to investigate the feasibility of electronic self-reporting of symptoms and whether there are significant correlations between different reported symptoms.

CLINICAL STUDY

#rpm

#software

View Analyst & Ambassador Comments
Go to original news
Jan 07,2019

Kaiku Health starts collaboration with a large biotech company in cancer immunotherapies

Finnish health data science company Kaiku Health, which develops complementary digital health interventions in oncology, has entered into a collaboration with Roche to develop unique patient support in cancer immunotherapy. The collaboration brings together the expertise of Roche in cancer immunotherapies and global market access with the competence of Kaiku Health in developing digital symptom management and clinical implementations in routine care. The objective of the collaboration is to develop personalised care and access for cancer patients in close collaboration and co-creation with patients and healthcare providers.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Dec 12,2019

Research shows that machine learning can be used to predict the onset and continuity of symptoms on patients receiving immune checkpoint inhibitor therapies

The results indicate that machine learning-based modeling of patient-reported symptom data on ICI treated cancer patients can predict the onset and continuity of symptoms related to ICI toxicities. The best performance considering all metrics was found for shortness of breath, joint pain, cough and fatigue. Importantly, all 14 symptom prediction models performed at a good level.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 16,2018

Results of the eCO trial published in the Journal of Clinical Oncology Informatics

The study, published as “Technology APPlications: Use of digital health technology to enable drug development,” examined the feasibility, usability and perceived satisfaction with eCO (eCediranib-Olaparib), a mobile application for side effect monitoring and reporting, in women with recurrent ovarian cancer. The eCO app was specifically designed to assist in managing acute treatment-related events such as hypertension and diarrhea, which are most often associated with treatment discontinuation, the need for drug holidays or dose interruptions/modifications. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 31,2018

Voluntis Announces the Launch of Theraxium Oncology, an Innovative Digital Platform for Symptom Management

Voluntis, a digital biotech specialized in digital therapeutics, announces the launch its Theraxium Oncology offer, a breakthrough technology that leverages digital therapeutics to empower patients so they can self-manage their symptoms, experienced when receiving cancer treatments, in coordination with care teams. Theraxium Oncology takes advantage of over four years of research and development by Voluntis in partnership with life science partners and cancer institutes as well as user feedback from patients and multiple US cancer centers.

PRODUCT

#software

#mobile app

#pdt

View Analyst & Ambassador Comments
Go to original news
Aug 30,2018

Voluntis Extends Partnership with AstraZeneca in Digital Therapeutics for Oncology

Voluntis (Paris:VTX), a digital biotech specialized in digital therapeutics, has announced the extension of its collaboration with AstraZeneca (NYSE: AZN) in the field of oncology. As part of the renewed agreement, the partners will implement a new phase of clinical evaluation of their digital therapeutic designed to support platinum resistant ovarian cancer patients treated with a combination of Cediranib plus Olaparib. The eCO (eCediranib/Olaparib) solution will be tested in the GY005 randomized phase III clinical trial sponsored by the National Cancer Institute (NCI), which will evaluate if the digital therapeutic can complement treatment by determining whether it enables better management of side effects and thereby improves patient outcomes.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 23,2018

Voluntis and Roche Pharma France reinvent cancer patient support with digital therapeutics

Today, Voluntis and Roche Pharma France announced that important milestones have been reached in the development of ZEMY, a digital therapeutic developed by Roche Pharma France in partnership with Voluntis since 2015. ZEMY aims to improve care support for breast cancer patients. Its co-construction with various stakeholders (patients, healthcare professionals, etc.) has been critical in developing its medical algorithms and validating its ease of use.

PRODUCT

#mobile app

#rpm

View Analyst & Ambassador Comments
Go to original news
Sep 20,2018

First-Half 2018: Expanded and strengthened abilities to pursue future growth

Voluntis announces its revenue and results for the first half of 2018, closed as of 30 June 2018.H1 2018 revenue of €2.2 million, reflecting the evolution of the revenue structure, and EBIT of -€7.9 million due to an increase in staff costs. Successful initial public offering, establishing cash of €28.6 million at end-June 2018.

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 24,2018

Voluntis announces end of multi-cancer extension for solution developed with Roche Pharma France

Voluntis announces Roche Pharma France’s decision to end the agreement, announced in March 2018, to extend the ZEMY solution, initially developed in breast cancer, to all solid tumors. In breast cancer, Roche Pharma France will continue to sponsor the ongoing clinical study. This multi-center study aims to evaluate user adherence to the ZEMY solution and the effect on patient quality of life. Voluntis will continue to develop its proprietary multi-cancer solution to manage a wide range of treatments and mechanisms of action for patients and healthcare professionals.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Oct 29,2018

Voluntis and AstraZeneca Win Prestigious Prix Galien MedStartUp Award for ‘Best Patient Engagement Technologies’ for eCO

Voluntis and AstraZeneca (NYSE: AZN) announced that they have been awarded the 2018 Prix Galien – MedStartUp Award for Best Patient Engagement Technology for eCO. eCO is a companion digital therapeutic developed by Voluntis, in partnership with AstraZeneca and the National Cancer Institute, for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of Cediranib plus Olaparib.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY